TY - JOUR
T1 - Whole-genome landscape of adult T-cell leukemia/lymphoma
AU - Kogure, Yasunori
AU - Kameda, Takuro
AU - Koya, Junji
AU - Yoshimitsu, Makoto
AU - Nosaka, Kisato
AU - Yasunaga, Jun ichirou
AU - Imaizumi, Yoshitaka
AU - Watanabe, Mizuki
AU - Saito, Yuki
AU - Ito, Yuta
AU - McClure, Marni B.
AU - Tabata, Mariko
AU - Shingaki, Sumito
AU - Yoshifuji, Kota
AU - Chiba, Kenichi
AU - Okada, Ai
AU - Kakiuchi, Nobuyuki
AU - Nannya, Yasuhito
AU - Kamiunten, Ayako
AU - Tahira, Yuki
AU - Akizuki, Keiichi
AU - Sekine, Masaaki
AU - Shide, Kotaro
AU - Hidaka, Tomonori
AU - Kubuki, Yoko
AU - Kitanaka, Akira
AU - Hidaka, Michihiro
AU - Nakano, Nobuaki
AU - Utsunomiya, Atae
AU - Sica, R. Alejandro
AU - Acuna-Villaorduna, Ana
AU - Janakiram, Murali
AU - Shah, Urvi
AU - Ramos, Juan Carlos
AU - Shibata, Tatsuhiro
AU - Takeuchi, Kengo
AU - Takaori-Kondo, Akifumi
AU - Miyazaki, Yasushi
AU - Matsuoka, Masao
AU - Ishitsuka, Kenji
AU - Shiraishi, Yuichi
AU - Miyano, Satoru
AU - Ogawa, Seishi
AU - Ye, B. Hilda
AU - Shimoda, Kazuya
AU - Kataoka, Keisuke
N1 - Funding Information:
The authors thank Shizue Ichimura, Fumie Ueki, Miki Sagou, Yoko Hokama, and Yoshiko Ito for technical assistance. The supercomputing resources were provided by the Human Genome Center, the Institute of Medical Science, The University of Tokyo. The Genomic Variation in Diffuse Large B Cell Lymphomas Study (phs001444.v2.p1) was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health (NIH), US Department of Health and Human Services. The datasets have been accessed through the NIH database for Genotypes and Phenotypes (dbGaP). A full list of acknowledgments can be found in the supplemental note of reference 35. This work was supported by the Japan Society for the Promotion of Science KAKENHI (JP21H04809 [K.K.] and JP21H05051 [K.K.]), Japan Agency for Medical Research and Development (JP21ck0106538 [K. Shimoda and K.K.], JP19ck0106254 [K. Shimoda and K.K.], JP19ak0101064 [K.K.]), Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research on Innovative Areas (JP18H04907 [K.K.]), Japan Science and Technology Agency Moonshot R&D Program (JPMJMS2022 [K.K.]), Daiichi Sankyo Foundation of Life Science (K.K.), Takeda Science Foundation (K.K.), The Japanese Society of Hematology Research Grant (K.K.), a pilot grant from the Albert Einstein Cancer Center (B.H.Y), and the National Institutes of Health National Cancer Institute Cancer Center Support Grant (P30 CA008748 [U.S.]).
Publisher Copyright:
© 2022 American Society of Hematology
PY - 2022/2/17
Y1 - 2022/2/17
N2 - Adult T-cell leukemia/lymphoma (ATL) is an aggressive neoplasm immunophenotypically resembling regulatory T cells, associated with human T-cell leukemia virus type-1. Here, we performed whole-genome sequencing (WGS) of 150 ATL cases to reveal the overarching landscape of genetic alterations in ATL. We discovered frequent (33%) loss-of-function alterations preferentially targeting the CIC long isoform, which were overlooked by previous exome-centric studies of various cancer types. Long but not short isoform–specific inactivation of Cic selectively increased CD4+CD25+Foxp3+ T cells in vivo. We also found recurrent (13%) 3′-truncations of REL, which induce transcriptional upregulation and generate gain-of-function proteins. More importantly, REL truncations are also common in diffuse large B-cell lymphoma, especially in germinal center B-cell–like subtype (12%). In the non-coding genome, we identified recurrent mutations in regulatory elements, particularly splice sites, of several driver genes. In addition, we characterized the different mutational processes operative in clustered hypermutation sites within and outside immunoglobulin/T-cell receptor genes and identified the mutational enrichment at the binding sites of host and viral transcription factors, suggesting their activities in ATL. By combining the analyses for coding and noncoding mutations, structural variations, and copy number alterations, we discovered 56 recurrently altered driver genes, including 11 novel ones. Finally, ATL cases were classified into 2 molecular groups with distinct clinical and genetic characteristics based on the driver alteration profile. Our findings not only help to improve diagnostic and therapeutic strategies in ATL, but also provide insights into T-cell biology and have implications for genome-wide cancer driver discovery.
AB - Adult T-cell leukemia/lymphoma (ATL) is an aggressive neoplasm immunophenotypically resembling regulatory T cells, associated with human T-cell leukemia virus type-1. Here, we performed whole-genome sequencing (WGS) of 150 ATL cases to reveal the overarching landscape of genetic alterations in ATL. We discovered frequent (33%) loss-of-function alterations preferentially targeting the CIC long isoform, which were overlooked by previous exome-centric studies of various cancer types. Long but not short isoform–specific inactivation of Cic selectively increased CD4+CD25+Foxp3+ T cells in vivo. We also found recurrent (13%) 3′-truncations of REL, which induce transcriptional upregulation and generate gain-of-function proteins. More importantly, REL truncations are also common in diffuse large B-cell lymphoma, especially in germinal center B-cell–like subtype (12%). In the non-coding genome, we identified recurrent mutations in regulatory elements, particularly splice sites, of several driver genes. In addition, we characterized the different mutational processes operative in clustered hypermutation sites within and outside immunoglobulin/T-cell receptor genes and identified the mutational enrichment at the binding sites of host and viral transcription factors, suggesting their activities in ATL. By combining the analyses for coding and noncoding mutations, structural variations, and copy number alterations, we discovered 56 recurrently altered driver genes, including 11 novel ones. Finally, ATL cases were classified into 2 molecular groups with distinct clinical and genetic characteristics based on the driver alteration profile. Our findings not only help to improve diagnostic and therapeutic strategies in ATL, but also provide insights into T-cell biology and have implications for genome-wide cancer driver discovery.
UR - http://www.scopus.com/inward/record.url?scp=85123529259&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123529259&partnerID=8YFLogxK
U2 - 10.1182/blood.2021013568
DO - 10.1182/blood.2021013568
M3 - Article
C2 - 34695199
AN - SCOPUS:85123529259
SN - 0006-4971
VL - 139
SP - 967
EP - 982
JO - Blood
JF - Blood
IS - 7
ER -